Uncategorized

Bharat Biotech submits Covaxin phase 3 trials data to DCGI

Bharat Biotech has submitted data from phase 3 trials of the Covaxin vaccine to the Drugs Controller General of India (DCGI). Covaxin is among three vaccines being used in the nationwide drive against Covid-19. It was granted approval by the DCGI in January, along with the Oxford University-AstraZeneca Vaccine which is being manufactured by the Pune-based Serum Institute of India (SII) as Covishield.

A third vaccine, Russia’s Sputnik V, was also granted emergency use authorisation (EUA) in April.

 

The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies